Suppliers / Otsuka Pharmaceutical India

Otsuka Pharmaceutical India

Japan 46 employees Updated 9 July 2026

Otsuka Pharmaceutical India is an API and finished-dose manufacturer based in Japan. It holds one active US drug master file across a filed portfolio of 9 molecules. Its filings concentrate with EDA (EG), BPOM (ID) and AIFA (IT). Its GMP standing is certified by BPOM (ID), US FDA and ZLG (DE), among 12 authorities. Its most recent recorded inspection, by US FDA, closed on 10 October 2025 as NAI. Customs aggregates show $20.5M of exports covering 1,991 molecules to 61 destinations in 2025.

1
active US DMFs
0
valid CEPs
12
registered plants 3 with an FDA FEI number
1,105
filings across 36 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
3 of 3 confirmed
Inspections
6 of 8 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 10 October 2025 NAI US FDA
  • 11 July 2025 VAI US FDA
  • 17 June 2025 VAI US FDA
  • 16 May 2025 NAI US FDA
  • 28 June 2024 NAI US FDA
  • 22 March 2024 VAI US FDA
  • 15 September 2023 NAI US FDA
  • 6 December 2022 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Chiyoda-Ku Tokyo, Canada Not on file
Opfikon, Switzerland Not on file
Munich, Germany Not on file
Barcelona, Spain Not on file
KAB. MALANG, Indonesia Not on file
-, Indonesia Not on file

6 further sites are on record.

What they file, and where

Molecule Regulators Docs
Dextrose DAV (Vietnam) 2
Cystein DAV (Vietnam) 1
Glutamic Acid DAV (Vietnam) 1
Lysine DAV (Vietnam) 1
Natri Clorid DAV (Vietnam) 1
Natri Lactat DAV (Vietnam) 1
Potassium DAV (Vietnam) 1
Serine DAV (Vietnam) 1
Tazobactam US FDA 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
EDA (EG) 110 2
BPOM (ID) 109 24
AIFA (IT) 104 None
FAMHP (BE) 88 None
DH (HK) 83 None
URPL (PL) 65 None
US FDA None 7
ZLG (DE) None 6
CDSCO (India) None 4
MFDS (Korea) None 4
NCELS (KZ) None 3
HSA (SG) None 2
AEMPS (ES) None 1
FDA (GH) None 1
ANVISA (Brazil) None 1
EMA None 1

Scale

Year Revenue Exports Destinations
2026 YTD Not reported $3.0M 33
2025 Not reported $20.5M 61
2024 Not reported $15.8M 53
2023 Not reported $16.4M 59

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. Otsuka Pharmaceutical India comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 10 October 2025.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Customs aggregates
Export values, molecule and destination counts